4.97
+0.81%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jinyao Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600488.SS. It has been listed since 18 June 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.91bn and net income of CN¥70.6m. At that date it held total assets of CN¥5.76bn and shareholders' equity of CN¥3.03bn.
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, development, production, and sales of corticosteroids and amino acid raw materials and preparations. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2001-06-18. The firm's main products include dexamethasone series, prednisone series, methylprednisolone series, betamethasone series and more than 40 varieties of corticosteroid raw materials, 23 varieties of amino acid raw materials, and 16 dosage forms such as tablets, injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, and inhalation preparations. The firm mainly operates in the domestic market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jun 2001
- Employees
- 2,569
- Website
- tjpcty.com ↗
Leadership
Pay as last reported
- Mr. Hua XuChairman of the Board, since 2022
- Mr. Liyan ZhuChief Financial Officer, Director, since 2021
- Mr. Shuxiang LiGeneral Manager, Director, since 2023
- Mr. Hao LiuDeputy General Manager, Director, since 2023
- Ms. Xiaoyan YangDeputy General Manager
- Mr. Jie ZhangDeputy General Manager, since 2014
- Ms. Chunli WangSecretary of the BoardCN¥462,500
- Mr. Min GuoDirector
- Mr. Xiaoyang XuDirector
- Mr. Hong BianIndependent Director
- Ms. Zhe ChenIndependent Director
- Mr. Wenxun HuoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jinyao Pharmaceutical's 40+ corticosteroid raw materials support domestic market dominance.
- 23 amino acid raw materials and 16 dosage forms enhance product diversity.
- 2,569 employees ensure robust R&D and production capabilities in Tianjin.
Weaknesses
- Limited overseas market presence compared to domestic operations.
- Dependence on corticosteroid and amino acid raw material production.
- No mention of international expansion strategies in business description.
Opportunities
- Growing demand for corticosteroid raw materials in global pharmaceutical markets.
- Expanding amino acid raw material applications in health care sectors.
- Potential for increased overseas market share in pharmaceutical exports.
Threats
- Competition from domestic pharmaceutical firms in Tianjin.
- Regulatory changes affecting corticosteroid production in China.
- Overreliance on domestic market for revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.